Guanylate cyclase stimulators for pulmonary hypertension-Reference-Cited by-同舟云学术

Guanylate cyclase stimulators for pulmonary hypertension

Published:2016-08-02 Issue:8 Volume:2016 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wardle Andrew J¹,Seager Matthew J²,Wardle Richard³,Tulloh Robert MR⁴,Gibbs J Simon R⁵

Affiliation:

1. Imperial College London; Cardiology, Hammersmith Hospital; Norfolk Place London UK W2 1PG

2. Imperial College London; Academic Section of Vascular Surgery; Charing Cross Hospital Fulham Palace Road London UK W6 8RF

3. Queens Medical Centre; Nottingham UK

4. Bristol Royal Hospital for Children and Bristol Heart Institute; Congenital Heart Disease; Upper Maudlin Street Bristol UK BS2 8BJ

5. Imperial College London; National Heart & Lung Institute; London UK

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011205.pub2/epdf/full

Reference108 articles.

1. Riociguat for HF with pulmonary hypertension (PH): Post-hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG);Bonderman;Journal of Cardiac Failure,2014

2. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study;Bonderman;Circulation,2013

3. Bonderman D Ghio S Felix SB Ghofrani HA Michelakis ED Mitrovic V Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post-hoc analysis of the phase IIB double-blind, randomized, placebo-controlled, dose-ranging hemodynamic LEPHT study American Heart Association Scientific Sessions; 2013 Nov 16-20; Dallas 2013 A17234

4. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design;Ghio;European Journal of Heart Failure,2012

5. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT);Semigran;Circulation,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension;Respiratory Research;2024-03-30

2. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health;The Journal of Sexual Medicine;2023-12-26

3. Interstitial lung diseases and secondary pulmonary hypertension;Srpski medicinski casopis Lekarske komore;2023

4. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide;Frontiers in Pediatrics;2022-12-01

5. Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021;Frontiers in Pharmacology;2022-08-23